ValueQ4, 24Q1, 25TTMSelling/general/admin expenses123.02 M139.6 M521.15 MResearch & development213.25 M199.92 M812.68 MOperating income235.22 M251.34 M936.67 MNon-Operating Income, Total46 K219 K266 KInterest expense, net of interest capitalized———Non-Operating Income, excl. Interest Expenses000Unusual income/expense46 K219 K266 KPretax income235.26 M251.56 M936.94 MEquity in earnings———Taxes8.16 M57.22 M169.78 MNon-controlling/minority interest———After tax other income/expense2.35 M2.02 M8.84 MNet income before discontinued operations244.53 M210.47 M833.42 MDiscontinued operations———Net income244.53 M210.47 M833.42 MDilution adjustment———Preferred dividends———Diluted net income available to common stockholders244.53 M210.47 M833.42 MBasic earnings per share (Basic EPS)0.910.813.12Diluted earnings per share (Diluted EPS)0.890.793.02Average basic shares outstanding271.57 M258.33 M—Diluted shares outstanding281.86 M267.32 M—EBITDA242.16 M258.29 M965.33 MEBIT235.22 M251.34 M936.67 MCost of revenue26.48 M19.95 M84.48 MOther cost of goods sold———Depreciation & amortization (cash flow)6.95 M6.95 M28.66 M
Exelixis, Inc. - Common Stock
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.